Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jan;73(1):5–12. doi: 10.1038/bjc.1996.2

Oestrogen receptor: a stable phenotype in breast cancer.

J F Robertson 1
PMCID: PMC2074280  PMID: 8554983

Abstract

Oestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70% of tumours that show acquired resistance the mechanism may be changed in ER status from positive to negative. This paper proposes an alternative hypothesis that ER expression in a stable phenotype in breast cancer. The paper reviews the literature on ER expression during the natural history of breast cancer in patients and also presents data on the effect of endocrine therapy on ER expression. If the alternative hypothesis is true it has important implications for treatment from chemoprevention to acquired endocrine resistance in advanced disease. Equally, if the hypothesis is true, attempts to develop laboratory models of endocrine resistance where ER-positive tumours become ER negative need to be re-evaluated.

Full text

PDF
5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra J. C., Barlock A., Huff K. K., Lippman M. E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer. 1980 Feb 15;45(4):792–794. doi: 10.1002/1097-0142(19800215)45:4<792::aid-cncr2820450430>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  2. Anderson E. D., Forrest A. P., Levack P. A., Chetty U., Hawkins R. A. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer. Br J Cancer. 1989 Aug;60(2):223–226. doi: 10.1038/bjc.1989.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benner S. E., Clark G. M., McGuire W. L. Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer. Am J Med Sci. 1988 Jul;296(1):59–66. doi: 10.1097/00000441-198807000-00011. [DOI] [PubMed] [Google Scholar]
  4. Brooks S. C., Saunders D. E., Singhakowinta A., Vaitkevicius V. K. Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy. Cancer. 1980 Dec 15;46(12 Suppl):2775–2778. doi: 10.1002/1097-0142(19801215)46:12+<2775::aid-cncr2820461406>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  5. Brünner N., Boulay V., Fojo A., Freter C. E., Lippman M. E., Clarke R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res. 1993 Jan 15;53(2):283–290. [PubMed] [Google Scholar]
  6. Brünner N., Frandsen T. L., Holst-Hansen C., Bei M., Thompson E. W., Wakeling A. E., Lippman M. E., Clarke R. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 1993 Jul 15;53(14):3229–3232. [PubMed] [Google Scholar]
  7. Bur M. E., Zimarowski M. J., Schnitt S. J., Baker S., Lew R. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 1992 Mar 1;69(5):1174–1181. doi: 10.1002/cncr.2820690518. [DOI] [PubMed] [Google Scholar]
  8. Buzdar A. U., Powell K. C., Blumenschein G. R. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res. 1982 Aug;42(8 Suppl):3448s–3450s. [PubMed] [Google Scholar]
  9. Campbell F. C., Blamey R. W., Elston C. W., Morris A. H., Nicholson R. I., Griffiths K., Haybittle J. L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1981 Dec 12;2(8259):1317–1319. doi: 10.1016/s0140-6736(81)91341-6. [DOI] [PubMed] [Google Scholar]
  10. Clark G. M., McGuire W. L. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol. 1988 Apr;15(2 Suppl 1):20–25. [PubMed] [Google Scholar]
  11. Clarke R. B., Laidlaw I. J., Jones L. J., Howell A., Anderson E. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer. 1993 Mar;67(3):606–611. doi: 10.1038/bjc.1993.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Clarke R., Skaar T., Baumann K., Leonessa F., James M., Lippman J., Thompson E. W., Freter C., Brunner N. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat. 1994;31(2-3):237–248. doi: 10.1007/BF00666157. [DOI] [PubMed] [Google Scholar]
  13. Cooke T., George D., Shields R., Maynard P., Griffiths K. Oestrogen receptors and prognosis in early breast cancer. Lancet. 1979 May 12;1(8124):995–997. doi: 10.1016/s0140-6736(79)92752-1. [DOI] [PubMed] [Google Scholar]
  14. Coombes R. C., Powles T. J., Berger U., Wilson P., McClelland R. A., Gazet J. C., Trott P. A., Ford H. T. Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet. 1987 Sep 26;2(8561):701–703. doi: 10.1016/s0140-6736(87)91071-3. [DOI] [PubMed] [Google Scholar]
  15. Croton R., Cooke T., Holt S., George W. D., Nicolson R., Griffiths K. Oestrogen receptors and survival in early breast cancer. Br Med J (Clin Res Ed) 1981 Nov 14;283(6302):1289–1291. doi: 10.1136/bmj.283.6302.1289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Daly R. J., Darbre P. D. Cellular and molecular events in loss of estrogen sensitivity in ZR-75-1 and T-47-D human breast cancer cells. Cancer Res. 1990 Sep 15;50(18):5868–5875. [PubMed] [Google Scholar]
  17. Davis B. W., Zava D. T., Locher G. W., Goldhirsch A., Hartmann W. H. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol. 1984 Mar;20(3):375–382. doi: 10.1016/0277-5379(84)90084-1. [DOI] [PubMed] [Google Scholar]
  18. DeFriend D. J., Howell A., Nicholson R. I., Anderson E., Dowsett M., Mansel R. E., Blamey R. W., Bundred N. J., Robertson J. F., Saunders C. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 1994 Jan 15;54(2):408–414. [PubMed] [Google Scholar]
  19. Encarnación C. A., Ciocca D. R., McGuire W. L., Clark G. M., Fuqua S. A., Osborne C. K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993;26(3):237–246. doi: 10.1007/BF00665801. [DOI] [PubMed] [Google Scholar]
  20. Eusebi V., Cerasoli P. T., Guidelli-Guidi S., Grilli S., Bussolati G., Azzopardi J. G. A two-stage immunocytochemical method for oestrogen receptor analysis: correlation with morphological parameters of breast carcinomas. Tumori. 1981 Aug;67(4):315–323. doi: 10.1177/030089168106700408. [DOI] [PubMed] [Google Scholar]
  21. Ewing T. M., Murphy L. J., Ng M. L., Pang G. Y., Lee C. S., Watts C. K., Sutherland R. L. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer. 1989 Oct 15;44(4):744–752. doi: 10.1002/ijc.2910440432. [DOI] [PubMed] [Google Scholar]
  22. Fabian C., Sternson L., El-Serafi M., Cain L., Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer. 1981 Aug 15;48(4):876–882. doi: 10.1002/1097-0142(19810815)48:4<876::aid-cncr2820480403>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  23. Fuqua S. A., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W., McGuire W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 1;51(1):105–109. [PubMed] [Google Scholar]
  24. Gaskell D. J., Hawkins R. A., Sangsterl K., Chetty U., Forrest A. P. Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet. 1989 May 13;1(8646):1044–1046. doi: 10.1016/s0140-6736(89)92445-8. [DOI] [PubMed] [Google Scholar]
  25. Giri D. D., Dundas S. A., Nottingham J. F., Underwood J. C. Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 1989 Dec;15(6):575–584. doi: 10.1111/j.1365-2559.1989.tb01623.x. [DOI] [PubMed] [Google Scholar]
  26. Gottardis M. M., Jiang S. Y., Jeng M. H., Jordan V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989 Aug 1;49(15):4090–4093. [PubMed] [Google Scholar]
  27. Gottardis M. M., Jordan V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988 Sep 15;48(18):5183–5187. [PubMed] [Google Scholar]
  28. Greene G. L., Jensen E. V. Monoclonal antibodies as probes for estrogen receptor detection and characterization. J Steroid Biochem. 1982 Mar;16(3):353–359. doi: 10.1016/0022-4731(82)90045-0. [DOI] [PubMed] [Google Scholar]
  29. Harland R. N., Barnes D. M., Howell A., Ribeiro G. G., Taylor J., Sellwood R. A. Variation of receptor status in cancer of the breast. Br J Cancer. 1983 Apr;47(4):511–515. doi: 10.1038/bjc.1983.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Harvey H. A., Lipton A., White D. S., Santen R. J., Boucher A. E., Shafik A. S., Dixon R. J. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res. 1982 Aug;42(8 Suppl):3451s–3453s. [PubMed] [Google Scholar]
  31. Hawkins R. A., Hill A., Freedman B. A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta. 1975 Oct 15;64(2):203–210. doi: 10.1016/0009-8981(75)90202-8. [DOI] [PubMed] [Google Scholar]
  32. Hawkins R. A., Hill A., Freedman B., Gore S. M., Roberts M. M., Forrest A. P. Reproducibility of measurements of oestrogen-receptor concentration in breast cancer. Br J Cancer. 1977 Sep;36(3):355–361. doi: 10.1038/bjc.1977.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hawkins R. A., Sangster K., Tesdale A., Levack P. A., Anderson E. D., Chetty U., Forrest A. P. The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and prediction of response to endocrine therapy. Br J Cancer. 1988 Jul;58(1):77–80. doi: 10.1038/bjc.1988.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Hawkins R. A., White G., Bundred N. J., Dixon J. M., Miller W. R., Stewart H. J., Forrest A. P. Prognostic significance of oestrogen and progestogen receptor activities in breast cancer. Br J Surg. 1987 Nov;74(11):1009–1013. doi: 10.1002/bjs.1800741118. [DOI] [PubMed] [Google Scholar]
  35. Howell A., Barnes D. M., Harland R. N., Redford J., Bramwell V. H., Wilkinson M. J., Swindell R., Crowther D., Sellwood R. A. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984 Mar 17;1(8377):588–591. doi: 10.1016/s0140-6736(84)90995-4. [DOI] [PubMed] [Google Scholar]
  36. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995 Jan 7;345(8941):29–30. doi: 10.1016/s0140-6736(95)91156-1. [DOI] [PubMed] [Google Scholar]
  37. Hähnel R., Twaddle E. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas. Breast Cancer Res Treat. 1985;5(2):155–163. doi: 10.1007/BF01805989. [DOI] [PubMed] [Google Scholar]
  38. Hähnel R., Woodings T., Vivian A. B. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979 Aug;44(2):671–675. doi: 10.1002/1097-0142(197908)44:2<671::aid-cncr2820440238>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  39. Jonat W., Maass H., Stegner H. E. Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res. 1986 Aug;46(8 Suppl):4296s–4298s. [PubMed] [Google Scholar]
  40. Kaye S. B., Woods R. L., Fox R. M., Coates A. S., Tattersall M. H. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res. 1982 Aug;42(8 Suppl):3445s–3447s. [PubMed] [Google Scholar]
  41. Kiang D. T., Kennedy B. J. Factors affecting estrogen receptors in breast cancer. Cancer. 1977 Oct;40(4):1571–1576. doi: 10.1002/1097-0142(197710)40:4<1571::aid-cncr2820400429>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  42. King W. J., Greene G. L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 1984 Feb 23;307(5953):745–747. doi: 10.1038/307745a0. [DOI] [PubMed] [Google Scholar]
  43. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  44. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  45. Lippman M. E., Allegra J. C. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer. 1980 Dec 15;46(12 Suppl):2829–2834. doi: 10.1002/1097-0142(19801215)46:12+<2829::aid-cncr2820461419>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  46. Malafa M., Chaudhuri B., Thomford N. R., Chaudhuri P. K. Estrogen receptors in ductal carcinoma in situ of breast. Am Surg. 1990 Jul;56(7):436–439. [PubMed] [Google Scholar]
  47. Margreiter R., Wiegele J. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer. Breast Cancer Res Treat. 1984;4(1):45–48. doi: 10.1007/BF01806987. [DOI] [PubMed] [Google Scholar]
  48. Markopoulos C., Berger U., Wilson P., Gazet J. C., Coombes R. C. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J (Clin Res Ed) 1988 May 14;296(6633):1349–1351. doi: 10.1136/bmj.296.6633.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Mason B. H., Holdaway I. M., Mullins P. R., Yee L. H., Kay R. G. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res. 1983 Jun;43(6):2985–2990. [PubMed] [Google Scholar]
  50. Masters J. R., Hawkins R. A., Sangster K., Hawkins W., Smith I. I., Shivas A. A., Roberts M. M., Forrest A. P. Oestrogen receptors, cellularity, elastosis and menstrual status in human breast cancer. Eur J Cancer. 1978 Mar;14(3):303–307. doi: 10.1016/0014-2964(78)90194-9. [DOI] [PubMed] [Google Scholar]
  51. Maynard P. V., Blamey R. W., Elston C. W., Haybittle J. L., Griffiths K. Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978 Nov;38(11 Pt 2):4292–4295. [PubMed] [Google Scholar]
  52. McClelland R. A., Berger U., Miller L. S., Powles T. J., Coombes R. C. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol. 1986 Aug;4(8):1171–1176. doi: 10.1200/JCO.1986.4.8.1171. [DOI] [PubMed] [Google Scholar]
  53. Moolgavkar S. H., Day N. E., Stevens R. G. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst. 1980 Sep;65(3):559–569. [PubMed] [Google Scholar]
  54. Morrow M., Jordan V. C. Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch Surg. 1993 Nov;128(11):1187–1191. doi: 10.1001/archsurg.1993.01420230015002. [DOI] [PubMed] [Google Scholar]
  55. Mullick A., Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 1990 Jan 15;50(2):333–338. [PubMed] [Google Scholar]
  56. Murphy C. S., Pink J. J., Jordan V. C. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res. 1990 Nov 15;50(22):7285–7292. [PubMed] [Google Scholar]
  57. Murray P. A., Gomm J., Ricketts D., Powles T., Coombes R. C. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. Eur J Cancer. 1994;30A(9):1218–1222. doi: 10.1016/0959-8049(94)90161-9. [DOI] [PubMed] [Google Scholar]
  58. Murray R. M., Pitt P. Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience. Cancer Res. 1982 Aug;42(8 Suppl):3437s–3441s. [PubMed] [Google Scholar]
  59. Namer M., Lalanne C., Baulieu E. E. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res. 1980 May;40(5):1750–1752. [PubMed] [Google Scholar]
  60. Newsome J. F., Avis F. P., Hammond J. E., Sherwood S. Sampling procedures in estrogen receptor determinations. Ann Surg. 1981 May;193(5):549–554. doi: 10.1097/00000658-198105000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Nicholson R. I., Bouzubar N., Walker K. J., McClelland R., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer. 1991;27(7):908–913. doi: 10.1016/0277-5379(91)90145-4. [DOI] [PubMed] [Google Scholar]
  62. Nicholson R. I., Colin P., Francis A. B., Keshra R., Finlay P., Williams M., Elston C. W., Blamey R. W., Griffiths K. Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers. Cancer Res. 1986 Aug;46(8 Suppl):4299s–4302s. [PubMed] [Google Scholar]
  63. Noguchi S., Miyauchi K., Nishizawa Y., Koyama H. Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behavior over time. Cancer. 1988 Apr 1;61(7):1345–1349. doi: 10.1002/1097-0142(19880401)61:7<1345::aid-cncr2820610712>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  64. Nomura Y., Tashiro H., Shinozuka K. Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer. Cancer. 1985 Feb 1;55(3):546–551. doi: 10.1002/1097-0142(19850201)55:3<546::aid-cncr2820550313>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  65. Osborne C. K., Coronado E., Allred D. C., Wiebe V., DeGregorio M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16;83(20):1477–1482. doi: 10.1093/jnci/83.20.1477. [DOI] [PubMed] [Google Scholar]
  66. Osborne C. K., Jarman M., McCague R., Coronado E. B., Hilsenbeck S. G., Wakeling A. E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994;34(2):89–95. doi: 10.1007/BF00685924. [DOI] [PubMed] [Google Scholar]
  67. Osborne C. K. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec;47(1-6):83–89. doi: 10.1016/0960-0760(93)90060-a. [DOI] [PubMed] [Google Scholar]
  68. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  69. Paik S., Hartmann D. P., Dickson R. B., Lippman M. E. Antiestrogen resistance in ER positive breast cancer cells. Breast Cancer Res Treat. 1994;31(2-3):301–307. doi: 10.1007/BF00666162. [DOI] [PubMed] [Google Scholar]
  70. Pallis L., Wilking N., Cedermark B., Rutqvist L. E., Skoog L. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res. 1992 Nov-Dec;12(6B):2113–2115. [PubMed] [Google Scholar]
  71. Paridaens R., Sylvester R. J., Ferrazzi E., Legros N., Leclercq G., Heuson J. C. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2889–2895. doi: 10.1002/1097-0142(19801215)46:12+<2889::aid-cncr2820461430>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  72. Peetz M. E., Nunley D. L., Moseley H. S., Keenan E. J., Davenport C. E., Fletcher W. S. Multiple simultaneous and sequential estrogen receptor values in patients with breast cancer. Am J Surg. 1982 May;143(5):591–594. doi: 10.1016/0002-9610(82)90170-2. [DOI] [PubMed] [Google Scholar]
  73. Poller D. N., Snead D. R., Roberts E. C., Galea M., Bell J. A., Gilmour A., Elston C. W., Blamey R. W., Ellis I. O. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer. 1993 Jul;68(1):156–161. doi: 10.1038/bjc.1993.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Roberts A. B., Frolik C. A., Anzano M. A., Sporn M. B. Transforming growth factors from neoplastic and nonneoplastic tissues. Fed Proc. 1983 Jun;42(9):2621–2626. [PubMed] [Google Scholar]
  75. Roberts M. M., Rubens R. D., King R. J., Hawkins R. A., Millis R. R., Hayward J. L., Forrest A. P. Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer. 1978 Sep;38(3):431–436. doi: 10.1038/bjc.1978.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Robertson J. F., Bates K., Pearson D., Blamey R. W., Nicholson R. I. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer. 1992 May;65(5):727–730. doi: 10.1038/bjc.1992.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Robertson J. F., Ellis I. O., Nicholson R. I., Robins A., Bell J., Blamey R. W. Cellular effects of tamoxifen in primary breast cancer. Breast Cancer Res Treat. 1992 Jan;20(2):117–123. doi: 10.1007/BF01834641. [DOI] [PubMed] [Google Scholar]
  78. Robertson J. F., Williams M. R., Todd J., Nicholson R. I., Morgan D. A., Blamey R. W. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol. 1989 Mar;25(3):469–475. doi: 10.1016/0277-5379(89)90259-9. [DOI] [PubMed] [Google Scholar]
  79. Sainsbury J. R., Farndon J. R., Sherbet G. V., Harris A. L. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet. 1985 Feb 16;1(8425):364–366. doi: 10.1016/s0140-6736(85)91385-6. [DOI] [PubMed] [Google Scholar]
  80. Samaan N. A., Buzdar A. U., Aldinger K. A., Schultz P. N., Yang K. P., Romsdahl M. M., Martin R. Estrogen receptor: a prognostic factor in breast cancer. Cancer. 1981 Feb 1;47(3):554–560. doi: 10.1002/1097-0142(19810201)47:3<554::aid-cncr2820470322>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  81. Sawka C. A., Pritchard K. I., Paterson A. H., Sutherland D. J., Thomson D. B., Shelley W. E., Myers R. E., Mobbs B. G., Malkin A., Meakin J. W. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 1986 Jun;46(6):3152–3156. [PubMed] [Google Scholar]
  82. Sharma A. K., Horgan K., Douglas-Jones A., McClelland R., Gee J., Nicholson R. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer. 1994 Jun;69(6):1032–1037. doi: 10.1038/bjc.1994.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Silfverswärd C., Skoog L., Humla S., Gustafsson S. A., Nordenskjöld B. Intratumoral variation of cytoplasmic and nuclear estrogen receptor concentrations in human mammary carcinoma. Eur J Cancer. 1980 Jan;16(1):59–65. doi: 10.1016/0014-2964(80)90108-5. [DOI] [PubMed] [Google Scholar]
  84. Smith I. E., Harris A. L., Morgan M., Ford H. T., Gazet J. C., Harmer C. L., White H., Parsons C. A., Villardo A., Walsh G. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) 1981 Nov 28;283(6304):1432–1434. doi: 10.1136/bmj.283.6304.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Soomro S., Shousha S., Sinnett H. D. Oestrogen and progesterone receptors in screen-detected breast carcinoma: an immunohistological study using paraffin sections. Histopathology. 1992 Dec;21(6):543–547. doi: 10.1111/j.1365-2559.1992.tb00442.x. [DOI] [PubMed] [Google Scholar]
  86. Straus M. J., Moran R., Muller R. E., Wotiz H. H. Estrogen receptor heterogeneity and the relationship between estrogen receptor and the tritiated thymidine labeling index in human breast cancer. Oncology. 1982;39(4):197–200. doi: 10.1159/000225636. [DOI] [PubMed] [Google Scholar]
  87. Thorpe S. M. Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method. Cancer Res. 1987 Dec 15;47(24 Pt 1):6572–6575. [PubMed] [Google Scholar]
  88. Tilley W. D., Keightley D. D., Cant E. L. Inter-site variation of oestrogen receptors in human breast cancers. Br J Cancer. 1978 Oct;38(4):544–546. doi: 10.1038/bjc.1978.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Toi M., Hamada Y., Nakamura T., Mukaida H., Suehiro S., Wada T., Toge T., Niimoto M., Hattori T. Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion. Int J Cancer. 1989 Feb 15;43(2):220–225. doi: 10.1002/ijc.2910430208. [DOI] [PubMed] [Google Scholar]
  90. Walker K. J., Bouzubar N., Robertson J., Ellis I. O., Elston C. W., Blamey R. W., Wilson D. W., Griffiths K., Nicholson R. I. Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res. 1988 Nov 15;48(22):6517–6522. [PubMed] [Google Scholar]
  91. Walker K. J., McClelland R. A., Candlish W., Blamey R. W., Nicholson R. I. Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue. Eur J Cancer. 1992;28(1):34–37. doi: 10.1016/0959-8049(92)90379-g. [DOI] [PubMed] [Google Scholar]
  92. Walt A. J., Singhakowinta A., Brooks S. C., Cortez A. The surgical implications of estrophile protein estimations in carcinoma of the breast. Surgery. 1976 Oct;80(4):506–512. [PubMed] [Google Scholar]
  93. Waseda N., Kato Y., Imura H., Kurata M. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res. 1981 May;41(5):1984–1988. [PubMed] [Google Scholar]
  94. Waseda N., Kato Y., Imura H., Kurata M. Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Res. 1981 May;41(5):1984–1988. [PubMed] [Google Scholar]
  95. Wilbur D. C., Barrows G. H. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Mod Pathol. 1993 Mar;6(2):114–120. [PubMed] [Google Scholar]
  96. Wilkinson P., Ribeiro G., Adam H., Patterson J. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer. Cancer Chemother Pharmacol. 1980;5(2):109–111. doi: 10.1007/BF00435413. [DOI] [PubMed] [Google Scholar]
  97. Williams M. R., Todd J. H., Ellis I. O., Dowle C. S., Haybittle J. L., Elston C. W., Nicholson R. I., Griffiths K., Blamey R. W. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer. 1987 Jan;55(1):67–73. doi: 10.1038/bjc.1987.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Yano T., Korkut E., Pinski J., Szepeshazi K., Milovanovic S., Groot K., Clarke R., Comaru-Schally A. M., Schally A. V. Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat. 1992;21(1):35–45. doi: 10.1007/BF01811962. [DOI] [PubMed] [Google Scholar]
  99. van den Berg H. W., Lynch M., Martin J., Nelson J., Dickson G. R., Crockard A. D. Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. Br J Cancer. 1989 Apr;59(4):522–526. doi: 10.1038/bjc.1989.107. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES